Dear Colleagues,

Lung cancer is still one of the most common malignancies world-wide and the leading cause of cancer death. Against the increasing incidence, screening by serum examination as well as diagnostic imaging gained subsequent higher detection rate in the early stage. Furthermore, as the therapeutic modality, recent progress of technique, machinery/tool and maneuverability in surgery greatly contributed to the improvement of treatment results. Finally, progress in precision medicine dealing with targeted agents have drastically changed the landscape of drug therapy, in particular, for adenocarcinoma. However, lung cancer is a sort of assembly by heterogeneous group, not only histologically, but also biologically, and thus, further clarification of the unknown patho-biological aspect of LC is inevitable. Based on this background, up-to-date notions for lung cancer is presented by experts in each field of lung cancer, i.e., pathologists, molecular biologists and surgeons.

Prof. Yoh Dobashi

Guest Editor